Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Nov;88(5):887-897.
doi: 10.1007/s00280-021-04338-7. Epub 2021 Aug 9.

A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors

Mingxiang Liao  1 , Krzysztof G Jeziorski  2   3   4 , Monika Tomaszewska-Kiecana  4 , István Láng  5 , Marek Jasiówka  6   7 , Viera Skarbová  8 , Piotr Centkowski  9 , Rodryg Ramlau  10 , Maria Górnaś  11 , John Lee  12 , Sarah Edwards  13 , Jenn Habeck  14 , Eileen Nash  15 , Nikolay Grechko  16 , Jim J Xiao  17
Affiliations
Clinical Trial

A phase 1, open-label, drug-drug interaction study of rucaparib with rosuvastatin and oral contraceptives in patients with advanced solid tumors

Mingxiang Liao et al. Cancer Chemother Pharmacol. 2021 Nov.

Abstract

Purpose: This study aimed at evaluating the effect of rucaparib on the pharmacokinetics of rosuvastatin and oral contraceptives in patients with advanced solid tumors and the safety of rucaparib with and without coadministration of rosuvastatin or oral contraceptives.

Methods: Patients received single doses of oral rosuvastatin 20 mg (Arm A) or oral contraceptives ethinylestradiol 30 µg + levonorgestrel 150 µg (Arm B) on days 1 and 19 and continuous doses of rucaparib 600 mg BID from day 5 to 23. Serial blood samples were collected with and without rucaparib for pharmacokinetic analysis.

Results: Thirty-six patients (n = 18 each arm) were enrolled and received at least 1 dose of study drug. In the drug-drug interaction analysis (n = 15 each arm), the geometric mean ratio (GMR) of maximum concentration (Cmax) with and without rucaparib was 1.29 for rosuvastatin, 1.09 for ethinylestradiol, and 1.19 for levonorgestrel. GMR of area under the concentration-time curve from time zero to last quantifiable measurement (AUC0-last) was 1.34 for rosuvastatin, 1.43 for ethinylestradiol, and 1.56 for levonorgestrel. There was no increase in frequency of treatment-emergent adverse events (TEAEs) when rucaparib was given with either of the probe drugs. In both arms, most TEAEs were mild in severity and considered unrelated to study treatment.

Conclusion: Rucaparib 600 mg BID weakly increased the plasma exposure to rosuvastatin or oral contraceptives. Rucaparib safety profile when coadministered with rosuvastatin or oral contraceptives was consistent with that of rucaparib monotherapy. Dose adjustments of rosuvastatin and oral contraceptives are not necessary when coadministered with rucaparib. ClinicalTrials.gov NCT03954366; Date of registration May 17, 2019.

Keywords: BCRP; Drug–drug interaction; Oncology; Oral contraceptives; Rucaparib.

PubMed Disclaimer

Conflict of interest statement

RR has served in a consulting or advisory role for Pfizer, Takeda, Boehringer Ingelheim, Roche, MSD, Novartis, and Bristol-Myers Squibb. EN has served in a consulting or advisory role for Bay Trials Unlimited, LLC. ML, JL, SE, JH, NG, and JX are employees of Clovis Oncology and may own stock or have stock options in that company. KGJ, MT-K, IL, MJ, VS, PC, and MG declare no conflict of interest.

Figures

Fig. 1
Fig. 1
Study design
Fig. 2
Fig. 2
Arithmetic mean (SD) plasma concentration–time profiles for rosuvastatin (A) and oral contraceptives, ethinylestradiol (B) and levonorgestrel (C), with and without rucaparib (PK analysis population). PK pharmacokinetics, SD standard deviation
Fig. 3
Fig. 3
The effect of rucaparib on the PK of rosuvastatin and oral contraceptives (DDI analysis population). AUC area under the concentration–time curve, AUC0–inf AUC extrapolated from time 0 to infinity, AUC0–last AUC from time 0 up to the last time point with a quantifiable concentration, CI confidence interval, Cmax maximum plasma concentration, DDI drug–drug interaction, GMR geometric mean ratio
See this image and copyright information in PMC

References

    1. Robillard L, Nguyen M, Harding TC, Simmons AD. In vitro and in vivo assessment of the mechanism of action of the PARP inhibitor rucaparib. Cancer Res. 2017 doi: 10.1158/1538-7445.AM2017-2475. - DOI
    1. Drew Y, Mulligan EA, Vong WT, Thomas HD, Kahn S, Kyle S, Mukhopadhyay A, Los G, Hostomsky Z, Plummer ER, Edmondson RJ, Curtin NJ. Therapeutic potential of poly(ADP-ribose) polymerase inhibitor AG014699 in human cancers with mutated or methylated BRCA1 or BRCA2. J Natl Cancer Inst. 2011;103(4):334–346. doi: 10.1093/jnci/djq509. - DOI - PubMed
    1. Rubraca (rucaparib) tablets [prescribing information] (2020). Clovis Oncology, Inc., Boulder
    1. Shapiro GI, Kristeleit R, Burris HA, LoRusso P, Patel MR, Drew Y, Giordano H, Maloney L, Watkins S, Goble S, Jaw-Tsai S, Xiao J. Pharmacokinetic study of rucaparib in patients with advanced solid tumors. Clin Pharmacol Drug Dev. 2019;8(1):107–118. doi: 10.1002/cpdd.575. - DOI - PMC - PubMed
    1. Kristeleit R, Shapiro GI, Burris HA, Oza AM, LoRusso P, Patel MR, Domchek SM, Balmana J, Drew Y, Chen LM, Safra T, Montes A, Giordano H, Maloney L, Goble S, Isaacson J, Xiao J, Borrow J, Rolfe L, Shapira-Frommer R. A phase I-II study of the oral PARP inhibitor rucaparib in patients with germline BRCA1/2-mutated ovarian carcinoma or other solid tumors. Clin Cancer Res. 2017;23(15):4095–4106. doi: 10.1158/1078-0432.CCR-16-2796. - DOI - PubMed

Publication types

MeSH terms

Associated data